🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination

RecruitingNAAges 18 Years - anyAllUniversity Hospital, Toulouse
NCT05945524 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * With multiple myeloma * Who receive Teclistamab * Consent form signed Exclusion Criteria: * Patient under legal protection
💊

What it tests

  • Bone marrow sampling
📍

Where

18 sites
CHU d'Amiens
Amiens, France
CHU de Caen
Caen, France
Polyclinique du Parc Drevon
Dijon, France
CH Annecy Genevois
Epagny Metz- Tessy, France
CHU de Lille
Lille, France
Centre Léon Bérard
Lyon, France
CHU de Montpellier
Montpellier, France
Hôpital Saint-Louis
Paris, France

…and 10 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy